Enveric Biosciences (ENVB) Change in Receivables (2014 - 2020)
Enveric Biosciences (ENVB) posted Change in Receivables of $268873.0 for Q3 2020, up 133.31% sequentially from -$807173.0 in Q2 2020.
Enveric Biosciences (ENVB) Change in Receivables (2014 - 2020) Analysis & Trends
Enveric Biosciences has reported Change in Receivables for 7 years, with the latest figure at $268873.0 in Q3 2020.
- Quarterly Change in Receivables changed N/A year-over-year to $268873.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was -$981352.0 (down 237.06% YoY) and the FY2019 annual result came in at -$1.5 million, down 53.8% from the prior year.
- Change in Receivables rose to $268873.0 in Q3 2020 per ENVB's latest filing, from -$807173.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $3.6 million in Q3 2016 and troughed at -$2.2 million in Q4 2019.
- A 5-year average of $149520.5 and a median of -$32575.5 in 2018 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2017 and 2019: Change in Receivables surged 2575.01% in 2017, then tumbled 5168.27% in 2019.
- Over 5 years, Change in Receivables stood at $335050.0 in 2016, then slumped by 198.09% to -$328635.0 in 2017, then jumped by 112.97% to $42631.0 in 2018, then sank by 5168.27% to -$2.2 million in 2019, then soared by 112.44% to $268873.0 in 2020.
- According to Business Quant data, Change in Receivables over the past three periods registered $268873.0, -$807173.0, and $1.7 million for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Enveric Biosciences | 5.62 Mn | -2.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 268,873.00 |
| Sep 30, 2020 | 268,873.00 |
| Jun 30, 2020 | -807,173.00 |
| Jun 30, 2020 | -807,173.00 |
| Mar 31, 2020 | 1.72 Mn |
| Mar 31, 2020 | 1.72 Mn |
| Dec 31, 2019 | -2.16 Mn |
| Dec 31, 2019 | -2.16 Mn |
| Jun 30, 2019 | -355,364.00 |
| Jun 30, 2019 | -355,364.00 |
| Mar 31, 2019 | 1.03 Mn |
| Mar 31, 2019 | 1.03 Mn |
| Dec 31, 2018 | 42,631.00 |
| Dec 31, 2018 | 42,631.00 |
| Sep 30, 2018 | -107,782.00 |
| Sep 30, 2018 | -107,782.00 |
| Jun 30, 2018 | -521,054.00 |
| Jun 30, 2018 | -521,054.00 |
| Mar 31, 2018 | -380,826.00 |
| Mar 31, 2018 | -380,826.00 |